FGF21 and obesity due to melanocortin 4 receptor deficiency: Since the debut in 2005 (1), fibroblast growth factor 21 (FGF21) has been of growing interest due to its dramatic beneficial effects at pharmacological levels on weight reduction and alleviation of obesity, diabetes, and fatty liver disease (2, 3).